Purpose: To compare dosimetric performance of volumetric-modulated arc therapy (VMAT) and small-spot intensity-modulated proton therapy for stage III non-smallcell lung cancer (NSCLC).
| INTRODUCTION
Lung cancer is the leading cause of cancer death among both men and women in the United States. Non-small-cell lung cancers (NSCLC) account for about 85% of lung cancer cases. 1, 2 Radiotherapy combined with chemotherapy is standard treatment for stage III NSCLC patients with unresectable tumors, but the potential toxic effects of radiation limit the feasibility for delivering adequate tumoricidal dose to targets in most patients. 3, 4 With photon radiation and concurrent chemotherapy, the long-term results from RTOG 0617
reported 5-year overall survival (5-year OS) of 32.1% (standard dose arm with 60 Gy) and 23% (high dose arm of 74 Gy) for unresectable NSCLC patients. 5 The fact that dose escalation has led to worse overall survival is possibly due to higher cardiac toxicity. 4, 6 The improvement of overall survival would require the minimization of incidental radiation dose to critical normal structures.
Volumetric-modulated arc therapy (VMAT) is an advanced form of intensity-modulated radiation therapy (IMRT) that can deliver a precisely sculpted dose distribution using a single or multi-arcs. 7 It has gained popularity in treating lung cancer patients due to its superior dose coverage, decreased radiation-induced pneumonitis, and shorter delivery time compared to conventional static-field IMRT. [8] [9] [10] [11] On the other hand, due to the sharp falloff of dose deposition distal to the Bragg peak, proton therapy has great potential to provide highly conformal tumor target coverage while sparing adjacent organs at risk (OARs), such as heart, lungs, spinal cord, and esophagus. 12, 13 Proton therapy is used in three different modalities:
passive-scattering proton therapy (PSPT), uniform scanning proton therapy (USPT), and intensity-modulated proton therapy (IMPT).
Recently, Chang et al. 14 published a phase 2 study of high dose PSPT (74 Gy [RBE] ) and concurrent chemotherapy for unresectable stage III NSCLC. They reported 5-year OS of 29% with very low rates of toxicities. It seemed that high dose PSPT tended to have better 5-year OS than the high dose photon therapy, but still slightly worse outcomes than the standard dose photon therapy if we compared this clinical trial data to RTOG 0617. Therefore, they suggested the use of IMPT to further improve the dose conformality and reduce doses to nearby OARs. 15, 16 Unfortunately, IMPT is subject to increased uncertainties for moving targets compared with PSPT and USPT. [17] [18] [19] Previous studies used proton pencil beam machines with in-air sigma at the isocenter as large as 6~15 mm (depending on proton energy) to treat NSCLC cancer. 15, 16 In this study, we defined these machines as large-spot proton machines compared to the proton pencil beam machines with in-air sigma at the isocenter of 2~6 mm (depending on proton energy), which we defined as small-spot proton machines for the purpose of this study.
There is a concern that IMPT with small-spot size may not be a good option for lung cancer treatments with large motions, due to the concerns of uncertainties and interplay effects. 20 A study by Chang et al.
suggested that thoracic malignancies with tumor motion larger than 5 mm may not be safely treated using IMPT. 21 Other studies suggested that IMPT treatment may be used for tumors with motion larger than 5 mm, but it would be negatively impacted by interplay effects, especially for small-spot IMPT. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] There are some studies that reported the limited impact of uncertainties and interplay effects in robustly optimized IMPT for stage III NSCLC. 34, 35 There are no reports about dosimetric comparison between small-spot IMPT and VMAT for NSCLC patients in term of plan quality, plan robustness in the face of uncertainties, and interplay effects.
IMPT with small-spot sizes has been used to treat non-moving targets for years. However, for moving targets such as lung cancer, previous researchers did demonstrate that small-spot IMPT could improve the treatment plan quality. 36 However, a simulation study showed that small-spot IMPT (σ: 2~4 mm) could be less robust toward motion and interplay effects than large-spot IMPT (σ: 8~17 mm). 28 Larger number of spots will be needed to cover the same target volume if small-spot proton machine was applied, which was also reported in a recent study. 37 In the same study it was stated that interplay effects should be considered before IMPT treatment plan was delivered to lung cancer patients. were the clinically applied.
The patients included in this study were carefully selected by experienced physicists from the existing database of treated patients to ensure that the patients from the two treatment groups did not show significant differences in age, motion amplitude, or prescription doses (Table 1) . However, the tumor size of patients treated by IMPT was significantly larger than that of patients treated with
VMAT. All patients were staged using PET/CT and brain CT scans to rule out metastatic disease. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and were definitively treated with radiation therapy with curative intent. None of the patients had implanted cardiac devices.
2.B | Patient simulation and immobilization
All patients were simulated using four-dimensional computed tomography (4D CT) in the supine position. Before image acquisition, the LIU ET AL. 
2.C | Target and normal tissue definition
Treatment targets were defined as follows. Co-registration with contrast enhanced CT scans and/or PET scans were used in identifying the gross target volume (GTV). The internal gross target volume CT artifacts were overridden using HU values sampled nearby.
2.D | Treatment planning
IMPT treatment planning generally followed the treatment planning guidelines recommended by the Particle Therapy Co-Operative Group (PTCOG) Thoracic and Lymphoma Subcommittee. 20 The proton beam scanning machine for IMPT treatment was commissioned to have an energy-dependent spot size (in-air σ) of 2 mm to 6 mm and a fixed spot spacing of 5 mm was chosen in treatment planning.
Discrete proton energies (from 71.3 to 228. plan using robust optimization was generated. The final plan was chosen by an experienced radiation oncologist after careful evaluation of plan quality, plan robustness, and interplay effects.
For IMPT plans, two verification plans were generated by recalculating the dose on the exhale and inhale 4D CT phases (without the density override) to evaluate the impact of respiratory motion.
The original plan was adjusted until the verification and original plan dose distributions met all the required dose volume constraints (Table 2) , plan robustness quantification thresholds, and the prescription criteria (see 2.F subsection).
In VMAT treatment planning, PTV was used for plan optimization. We applied photon optimizer (PO) model in the Eclipse™ for VMAT optimization, and analytical anisotropic algorithm (AAA) model for dose calculation. For target coverage, PTV high V 100% was at least 95% of prescription dose, and PTV high D 0.03 cc was not more than 110% of prescription dose. Most commonly, two or three arcs were used.
2.E | Plan quality evaluation
We calculated CTV D 95% , D 5% (the dose level covering at least 95% and 5% of the structure volume with the highest dose respectively), 
2.F | Robustness quantification
To evaluate the robustness of IMPT and VMAT plans, we used the For VMAT plans, we created six perturbed scenarios and one nominal scenario. The setup uncertainty caused by the rigid shift of the patient isocenter in the A-P, S-I, and R-L directions (±5mm) produced six perturbed scenarios. To generate these uncertainty scenarios, we manually shifted the isocenter (±5mm) and recalculated the VMAT plans in different uncertainty scenarios. DVH curves for these scenarios were determined in our TPS. We exported the DVH curves and calculated the width of DVH band using in-house developed software. We ensured that in the worst-case scenario the CTV D 95% was at least 95% of the prescription dose in the dose calculations done on all CTs.
2.G | Interplay effect evaluation
For IMPT treatment, the average energy layer switch time for all 97 energies was 1.91s, ranging from 1.9 to 2.0 s. The average spill length was 7.9s. The average magnet preparation and verification time was 1.93 ms. The effective magnet scanning speed in x-direction for high/medium and low energy groups were 5.7 and 7.0 m/s, respectively. The effective magnet scanning speed in y-direction for high, medium, and low energy groups were 17.1, 18.2, and 22.2 m/s, respectively. The proton spill rate in high, medium, and low energy groups were 9.8, 8.1, and 8.5 monitor unit/s (MU/s), respectively.
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The field information and delivery durations of IMPT and VMAT plans can be found in the supplementary material (Tables S2 and S3 ).
Iso-layer repainting was used to mitigate the impact of interplay effects. 35, 37, 39 If the respiratory motion amplitude was less than 5 mm, the minimum and maximum MU limits in the proton machine were 0.003 and 0.04 MU, respectively. Otherwise, they were 0.003 and 0.01 MU, respectively. Smaller maximum MU limits thereby enforced a higher number of iso-layer repainting for these patients to mitigate interplay effects. For our iso-layer repainting technique, a spot would be split into multiple spots if its intensity was larger than the maximum MU limit and the split spots would be appended at the end of the spot list of the same energy layer and delivered through the iso-layer repainting. A spot, which is planned to deliver
MUs smaller than the minimum MU limit, would be rounded up or down depending on whether the amount of MU was larger or smaller than half of the minimum MU limit. For example, with a mini- For IMPT plans, we developed software to calculate the dose under the influence of interplay effects. 29, 30, 40, 41 In the software, time-dependent spot delivery parameters, 4D CTs, and the time spent in each phase during the 4D CT simulations were used 39, 40, [42] [43] [44] to calculate the dose delivered in a patient with interplay effects considered.
We randomized the starting phase of each field per fraction to effectively mitigate the impact of the starting phase. 40 The results of the DVH indices were presented using median values of the corresponding DVH indices with error bars. The error bars indicate maximum and minimum values of the corresponding DVH indices from all patients.
No interplay effect evaluation was done for VMAT plans. (Table 4) .
3.B | Plan robustness

3.C | Interplay effect
Interplay effects were only considered for the IMPT plans as shown in Figs. 3(a)-3 VMAT gained popularity in the treatment of lung cancer patients due to its high conformality between the prescription iso-dose lines and targets. IMPT can spare more normal tissues than IMRT, including heart, spinal cord, lung, and esophagus, due to the characteristics of the Bragg peak. 15 Compared with IMRT, IMPT significantly However, the effectiveness of a treatment plan also depends on plan robustness to both uncertainties and interplay effects. Compared with IMPT, VMAT is more robust with respect to motions or changes in anatomy, 47 which is consistent with our study. IMPT could be enormously impacted by interplay effects for tumor motions larger than 10 mm and utilization of small-spot. 28, 30 Interestingly, our results show that IMPT can achieve clinically acceptable Both would lead to more severe interplay effects. 40 Due to the proper planning method we used, uncertainties and respiratory motion had limited impact on target coverage and homogeneity, and OAR protection, which is consistent with Inoue et al. 34 Our results are consistent with Inoue et al. 34 This is possibly due to the proper planning methods we used. Most of the IMPT plans included in this study were generated using SFO and the rest of them were generated using MFO with robust optimization from a commercial treatment planning system. Li et al. 30 cautiously extended their IMPT treatment with large spots to lung cancer patients with tumor motion over 5 mm. Our study further extended the applicability of small-spot IMPT to treat lung cancer patients with tumor motions larger than 5mm but smaller than 11 mm.
The patient groups selected for comparison are not completely statistically comparable. CTV volumes of the patients treated by
IMPT are larger than those of the patients treated by VMAT (Table 1) . A previous study suggested that large volumes could benefit plan robustness, but increase the difficulties in generating a plan of high quality in the case of IMPT. 
| CONCLUSION
Small-spot IMPT significantly improves sparing of spinal cord, heart, and lung compared to VMAT and achieves clinically acceptable plan robustness at least for the lung cancer patients included in this study with motion amplitude less than 11 mm. The impact of interplay effects is small if procedures described here are used. This study supports the feasibility of clinical use of small-spot IMPT to treat certain lung cancer patients. 
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